Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib in EGFR-driven Advanced Solid Tumours
NCT04946968Phase 2Active, not recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Aug 2021
- Primary completion
- Apr 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacomitinib in solid tumor (advanced stage), squamous cell carcinoma of the lung (SCCL) and head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Centre Singapore. Primary endpoint: Objective Response Rate at 36 months. Started Aug 2021; status: active, not recruiting.
02
Drugs
dacomitinib
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the lung (SCCL)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04946968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946968.